Brain atrophy by automated MRI reading in long-term natalizumab treated patients: Real world data suggests brain atrophy rates in range of healthy individuals

Supported by Biogen. DH: has received compensation for travel, speaker honoraria and consultant fees from Biogen, Novartis, Merck, Bayer, Sanofi Genzyme, and Teva, as well as research funding from Biogen. AL: has received research funding, honoraria as a speaker and member of advisory boards from Biogen, Sanofi Genzyme, Merck, Novartis, Bayer, Roche, Teva